Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1,4-Dithiothreitol (DTT) is a small molecule reducing agent widely used in biochemical and molecular biology research. Its primary function is to protect thiol (SH) groups in proteins and other molecules by preventing their oxidation and to reduce disulfide bonds to free thiols. DTT achieves this through its low redox potential (−0.33 V at pH 7), which allows it to maintain SH-groups in the reduced state more effectively than similar agents like 2-mercaptoethanol. Upon oxidation, DTT forms a stable six-membered ring via an intramolecular disulfide bond. This property makes it especially useful for enzyme isolation and purification as well as for reactivation of enzymes that require reduced cysteine residues for activity[1][2][8]. While primarily used as a laboratory reagent rather than a therapeutic drug, there are rare reports of experimental use in certain medical conditions such as nephropathic cystinosis[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1,4-dithiothreitol.